Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

BIVI

BioVie Inc

Feb 13 • 04:00PM ET

1.27

+0.16 14.41 %

Healthcare • Biotechnology • USA • NASD

Peers: BIIB LLY NBIX SAVA PRTA EQ ANVS ACAD AUTL AXSM

| Held by: VTI VXF

Index	-	P/E	-	EPS (ttm)	-5.08	Insider Own	4.75%	Shs Outstand	7.54M	Perf Week	12.39%
Market Cap	9.58M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	7.19M	Perf Month	4.96%
Enterprise Value	-10.65M	PEG	-	EPS next Q	-	Inst Own	18.55%	Short Float	2.71%	Perf Quarter	-21.12%
Income	-17.48M	P/S	-	EPS this Y	-	Inst Trans	17.80%	Short Ratio	2.02	Perf Half Y	-23.49%
Sales	0.00M	P/B	0.50	EPS next Y	-	ROA	-72.35%	Short Interest	0.19M	Perf YTD	9.48%
Book/sh	2.55	P/C	0.47	EPS next 5Y	-	ROE	-80.74%	52W High	18.75 -93.23%	Perf Year	-92.82%
Cash/sh	2.72	P/FCF	-	EPS past 3/5Y	51.42% 55.38%	ROIC	-89.64%	52W Low	1.06 19.81%	Perf 3Y	-99.75%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	9.85% 8.07%	Perf 5Y	-99.97%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	87.15%	Oper. Margin	-	ATR (14)	0.10	Perf 10Y	-99.90%
Dividend Ex-Date	-	Quick Ratio	7.25	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	53.87	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	7.25	EPS Q/Q	83.17%	SMA20	6.70%	Beta	0.55	Target Price	12.00
Payout	-	Debt/Eq	0.02	Sales Q/Q	-	SMA50	-2.32%	Rel Volume	2.15	Prev Close	1.11
Employees	13	LT Debt/Eq	0.01	Earnings	Dec 03	SMA200	-70.01%	Avg Volume	96.47K	Price	1.27
IPO	May 05, 2014	Option/Short	No / Yes	EPS/Sales Surpr.	0.00% -	Trades		Volume	207,761	Change	14.41%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-22-22	Initiated	Cantor Fitzgerald	Overweight	$7
Jan-15-21	Initiated	B. Riley Securities	Buy	$47

Feb-12-26 03:50PM	Dow drops below 50,000 as S&P 500 falls back under years opening level (Proactive)
08:33AM	BioVie highlights bezisterim research at ACP meeting (Proactive)
08:00AM	BioVie Announces Abstracts Accepted for Presentation at the 2026 American College of Psychiatrists Annual Meeting (GlobeNewswire)
Feb-11-26 10:30AM	BioVie could offer first new Parkinsons therapy in decades (Proactive)
Jan-08-26 08:00AM	BioVie Completes Enrollment in Phase 2 SUNRISE-PD Trial in Early Parkinson's Disease (GlobeNewswire)
02:05PM	Loading…
Dec-24-25 02:05PM	HALPER SADEH LLC ENCOURAGES BIOVIE INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS (PR Newswire)
Dec-11-25 12:00PM	What Makes BioVie (BIVI) a New Buy Stock (Zacks)
Nov-19-25 08:00AM	Join Biovie's Exclusive Live Investor Webinar and Q&A Session on December 9 (GlobeNewswire)
Oct-24-25 08:20AM	Halper Sadeh LLC Encourages BioVie Inc. Shareholders to Contact the Firm to Discuss Their Rights (Business Wire)
Sep-26-25 08:00AM	BioVie to Host Live Investor Webinar and Q&A on Oct. 8 (GlobeNewswire)
Aug-13-25 04:05PM	BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes (GlobeNewswire)
Aug-11-25 04:05PM	BioVie Inc. Announces Closing of $12 Million Public Offering (GlobeNewswire) +7.19% -6.70%
Aug-07-25 08:43PM	BioVie Inc. Announces Pricing of $12 Million Public Offering (GlobeNewswire) -25.58% -42.61%
Jul-24-25 08:00AM	BioVie Presented Data Highlighting that Patients Treated with Bezisterim Potentially Experienced an Age Deceleration Advantage Compared to Placebo on 10 Different Biological Clocks at the 2nd World Conference on Aging and Gerontology (GlobeNewswire) -8.37%
Jul-22-25 08:00AM	BioVie Appoints Industry Veterans Amy Chappell, MD, FAAN, and Kameel Farag to Board of Directors (GlobeNewswire) +12.04%
08:00AM	Loading…
Jul-09-25 08:00AM	BioVie Announces Data Highlighting Bezisterim's Potential to Slow or Reverse Biological Aging and Neurodegeneration Featured as a Keynote Talk at the 7th World Aging and Rejuvenation Conference (GlobeNewswire)
Jun-26-25 08:00AM	BioVie Highlights Patient-Centric Design of SUNRISE-PD Trial at Advanced Therapeutics in Movement & Related Disorders Congress (ATMRD) (GlobeNewswire)
Jun-24-25 04:05PM	BioVie to Present Overview of Phase 2 SUNRISE-PD Trial at the Advanced Therapeutics in Movement & Related Disorders Congress (GlobeNewswire) +5.94%
May-15-25 08:00AM	BioVie Enrolls First Patient in ADDRESS-LC Clinical Trial Assessing Novel Anti-Inflammatory Candidate Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID (GlobeNewswire)
May-14-25 07:30AM	BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease on May 28, 2025 (GlobeNewswire)
May-07-25 08:00AM	BioVie to Present Rationale and Design of Phase 2 SUNRISE-PD Clinical Trial at the 30th World Congress on Parkinson's Disease and Related Disorders (IAPRD 2025) (GlobeNewswire) -6.90%
May-05-25 08:00AM	BioVie Unveils Corporate Advisory Board Featuring Neuralink Co-Founder, Former Executives from Mastercard and Apple, and High-Impact Industry Leaders to Advance BioVie Mission and Growth (GlobeNewswire) -5.79%
Apr-16-25 08:00AM	BioVie Initiates SUNRISE-PD Clinical Trial Assessing Bezisterim in Early Parkinson's Disease with First Patient Enrolled (GlobeNewswire)
Mar-27-25 08:00AM	BioVie to Host KOL Investor Webcast to Discuss the Long COVID Treatment Landscape and its ADDRESS-LC Trial on April 10, 2025 (GlobeNewswire)
Mar-10-25 10:35AM	New to The Street Show 633 to Broadcast on Fox Business Network as Sponsored Programming Tonight at 10:30 PM PST Featuring Zapp Electric Vehicles ($ZAPP), BioVie ($BIVI), PetVivo ($PETV), and Banzai ($BNZI) (ACCESS Newswire) -8.40%
Mar-03-25 08:40PM	New to the Street Airs Show #630 on Fox Business Network Tonight at 10:30 PM PST Featuring Roadzen ($RDZN), BioVie ($BIVI), AtlasClear (ATCH), eXoZymes ($EXOZ), and EvolveHealthandLifestyle.com With Craig Bruce (ACCESS Newswire) -11.28%
Feb-22-25 12:15PM	New to The Street to Broadcast Live on Bloomberg Tonight at 6:30 PM EST as Sponsored Programming, Spotlighting BioVie (BIVI), RoadZen (RDZN), HPB, and Sustainable Innovation With Shark Tanks Kevin Harrington and Sustainable Green Team (SGTM) (ACCESS Newswire)
Jan-13-25 09:00AM	BioVie Inc. ($BIVI) Joins Forces With New to The Street for a Dynamic 6-Part Media Campaign Featuring Long-Form Interviews, National TV Commercials, Iconic Billboards, and Exclusive Accredited Events (ACCESS Newswire)
Nov-20-24 08:00AM	BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference (GlobeNewswire)
Nov-04-24 08:00AM	BioVie's Upcoming Parkinson's Disease Clinical Trial is Fully Funded (GlobeNewswire) -9.39%
04:05PM	Loading…
Oct-29-24 04:05PM	BioVie Inc. Announces Closing of Registered Direct Offering (GlobeNewswire) -10.80% +10.94%
Oct-28-24 04:10PM	UPDATE -- BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
03:13PM	BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Oct-24-24 04:10PM	BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement (GlobeNewswire) +5.45% +5.54%
Oct-23-24 03:24PM	BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -23.51%
09:19AM	BioVie Announces Stock Offering and Private Placement (TipRanks)
08:00AM	Join BioVie's Exclusive Live Investor Webinar and Q&A Session on November 7th, 2024 (GlobeNewswire)
Oct-22-24 04:01PM	BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement (GlobeNewswire) +27.76%
Oct-21-24 03:08PM	BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) +11.91%
Oct-15-24 08:00AM	BioVie Receives Notice of Allowance for Japan Patent Application Covering Novel Liquid Formulation of Terlipressin (GlobeNewswire)
Oct-11-24 09:00AM	BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
Oct-01-24 08:00AM	BioVie Receives Notice of Allowance for United States Patent Application Covering Novel Liquid Formulation of Terlipressin (GlobeNewswire)
Sep-25-24 04:05PM	BioVie Inc. Announces Closing of Public Offering (GlobeNewswire) -7.50%
Sep-23-24 10:26PM	BioVie Inc. Announces Pricing of Public Offering (GlobeNewswire) -57.86%
04:05PM	BioVie Inc. Announces Proposed Public Offering (GlobeNewswire)
Sep-16-24 08:00AM	BioVie Secures All Scientific Approvals Needed to Receive Additional $12.6 Million of Grant Funding to Launch Planned Phase 2 Trial to Evaluate Bezisterim in Long COVID (GlobeNewswire)
Sep-03-24 08:00AM	BioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long COVID (GlobeNewswire)
Aug-27-24 08:45AM	BioVie Announces Clinical Data Showing Epigenetic Basis for How Bezisterim May Modulate Inflammation and the Biological Aging Process at the 11th Aging Research and Drug Discovery Meeting (GlobeNewswire)
Aug-13-24 08:00AM	BioVie to Present Overview of Bezisterim Clinical Data on Longevity at 11th Aging Research and Drug Discovery Meeting (GlobeNewswire)
Aug-12-24 07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace) -10.08%
Aug-08-24 06:00AM	BioVie Announces Alignment with FDA on Clinical Trial to Assess Bezisterim in Parkinson's Disease (GlobeNewswire) +13.30%
Aug-06-24 04:40PM	BioVie Inc. Announces Reverse Stock Split (GlobeNewswire) -21.40% -5.63%
Jul-05-24 09:00AM	BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
Jun-25-24 08:00AM	BioVie Presents Protocol Design of Upcoming SUNRISE-PD Phase 2 Trial of Bezisterim in Patients with Early Parkinson's Disease at ATMRD 2024 (GlobeNewswire) -5.32%
Jun-21-24 09:00AM	BioVie and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
Jun-20-24 08:00AM	BioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson's Disease at 2024 ATMRD Congress (GlobeNewswire)
Jun-12-24 08:24AM	Join BioVie's Exclusive Live Investor Webinar and Q&A Session on June 26 (GlobeNewswire)
Jun-04-24 08:00AM	BioVie Announces Formation of Advisory Board for Bezisterim in Long COVID (GlobeNewswire)
May-22-24 08:00AM	BioVie's Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson's Disease Patients (GlobeNewswire)
May-15-24 10:53AM	BIVI Stock Earnings: BioVie Beats EPS for Q3 2024 (InvestorPlace)
Apr-29-24 11:43AM	BioVie Gets up to $13.1 Million From US Defense Department to Evaluate Bezisterim for Long COVID (MT Newswires)
08:00AM	BioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID (GlobeNewswire)
Apr-25-24 08:00AM	BioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore Homeostasis in a Manner Correlated with Alzheimer's Disease and Biomarker Endpoints (GlobeNewswire)
Apr-18-24 08:00AM	BioVie to Present Data Showing How NE3107 Potentially Restores Homeostasis via Specific Genes Associated with Dementia, Metabolism, and Inflammation (GlobeNewswire)
Apr-12-24 09:00AM	Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
Mar-26-24 10:30AM	Lawsuit Notice: Investors who lost money with BioVie Inc. (NASDAQ: BIVI) shares should contact the Shareholders Foundation (PR Newswire) -6.17%
Mar-13-24 11:30AM	SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioVie (PR Newswire) +6.93%
Mar-12-24 09:55AM	Bears are Losing Control Over BioVie Inc. (BIVI), Here's Why It's a 'Buy' Now (Zacks)
09:41AM	BioVie Sued By Block & Leviton LLP for Securities Law Violations (GlobeNewswire)
Mar-11-24 10:48AM	BioVie cuts 'most de-risked program,' will seek partners for phase-3 ready ascites program (FierceBiotech.com)
08:00AM	BioVie Announces Pipeline Update and Near-Term Clinical Priorities (GlobeNewswire)
Mar-06-24 06:21PM	BIVI INVESTORS: Lead Plaintiff is Quickly Approaching; Contact Robbins LLP for Information About Your Rights (GlobeNewswire) -8.02% -10.25%
05:00PM	BioVie Inc. Announces Closing of Public Offering (GlobeNewswire)
Mar-05-24 11:39AM	Investors in BioVie Inc. Should Contact Levi & Korsinsky Before March 19, 2024 to Discuss Your Rights BIVI (GlobeNewswire) -15.24%
Mar-04-24 05:16PM	BioVie Inc. investors: Please contact the Portnoy Law Firm to recover your losses; March 19, 2024 deadline. (GlobeNewswire) -43.65%
08:51AM	Why Is BioVie (BIVI) Stock Down 41% Today? (InvestorPlace)
01:32AM	BioVie Inc. Announces Pricing of Public Offering (GlobeNewswire)
Mar-01-24 04:58PM	BioVie Inc. Announces Proposed Public Offering of Common Stock (GlobeNewswire) +52.42%
04:58PM	BioVie Inc. Announces Proposed Public Offering of Common Stoc (GlobeNewswire)
10:57AM	Why Is BioVie (BIVI) Stock Up 100% Today? (InvestorPlace)
08:00AM	BioVie's NE3107 Demonstrates Potential Improvements in Motor and Non-motor Symptoms for Parkinson's Disease Patients and May Be Realigning Physiological Processes for Alzheimer's Patients in Data to be Presented at the International Conference on Alzheimer's and Parkinson's Diseases 2024 (GlobeNewswire)
Feb-23-24 04:49PM	Investors Sue BioVie (BIVI) After Potential Scientific Misconduct In Failed Phase 3 Clinical Trial Uncovered Hagens Berman (GlobeNewswire) -5.60%
12:30PM	BIOVIE SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In BioVie To Contact Him Directly To Discuss Their Options (GlobeNewswire)
05:45AM	BioVie Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIVI (PR Newswire)
Feb-19-24 01:12PM	Investors Sue BioVie (BIVI) After Potential Scientific Misconduct In Failed Phase 3 Clinical Trial Uncovered Hagens Berman (GlobeNewswire)
Feb-09-24 03:40PM	Investors Sue BioVie (BIVI) After Potential Scientific Misconduct In Failed Phase 3 Clinical Trial Uncovered Hagens Berman (GlobeNewswire) +6.36%
Feb-07-24 01:00PM	BioVie Sued By Block & Leviton LLP for Securities Law Violations (GlobeNewswire)
Feb-06-24 08:00AM	BioVie to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire) +5.83%
Jan-29-24 01:28PM	Investors Sue BioVie (BIVI) Action After Uncovering Potential Scientific Misconduct In Failed Phase 3 Clinical Trial Hagens Berman (GlobeNewswire) +12.07%
Jan-27-24 05:29AM	18 Best 52-Week Low Stocks To Buy Now (Insider Monkey)
Jan-25-24 12:34PM	Investors sue BioVie (BIVI) Action After Uncovering Potential Scientific Misconduct In Failed Phase 3 Clinical Trial Hagens Berman (GlobeNewswire)
Jan-24-24 11:30AM	BIOVIE SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In BioVie To Contact Him Directly To Discuss Their Options (GlobeNewswire)
Jan-19-24 07:18PM	BioVie Sued By Block & Leviton LLP for Securities Law Violations (GlobeNewswire)
Jan-17-24 03:14PM	HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages BioVie (BIVI) Investors with Substantial Losses to Contact its Attorneys, Firm Investigating Possible Securities Law Violations (GlobeNewswire)
Jan-11-24 10:25AM	BioVie (BIVI) Plunges After Alzheimer's Drug Fails Phase 3 Due to Protocol Deviations at Trial Sites Hagens Berman (GlobeNewswire)
Jan-05-24 02:08PM	BioVie (BIVI) Plunges After Alzheimer's Drug Fails Phase 3 Due to Protocol Deviations at Trial Sites Hagens Berman (GlobeNewswire)
09:00AM	bioAffinity Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV (ACCESSWIRE)
Dec-29-23 09:00AM	Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV (ACCESSWIRE)
Dec-25-23 11:15AM	BioVie (BIVI) Plunges After Alzheimer's Drug Fails Phase 3 Due to Protocol Deviations at Trial Sites Hagens Berman (GlobeNewswire)
Dec-22-23 09:00AM	Rail Vision and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV (ACCESSWIRE)

BioVie, Inc. is a biopharmaceutical company, which engages in discovery, development, and marketing drug therapies for neurological and neurodegenerative disorders, and liver disease. The company was founded on April 10, 2013 and is headquartered in Carson City, NV.

Open in Screener

CYRX

CryoPort Inc

Feb 13 • 04:00PM ET

8.35

+0.11 1.33 %

Industrials • Integrated Freight & Logistics • USA • NASD

Peers: TMO DHR BDX CTLT STE BRKR BIO AVTR ADPT ICUI

| Held by: VTI IWM VXF IWN VTWO SCHA VHT DFAS DFAC AVSC

Index	RUT	P/E	-	EPS (ttm)	-1.14	Insider Own	4.24%	Shs Outstand	50.07M	Perf Week	-4.24%
Market Cap	418.08M	Forward P/E	-	EPS next Y	-0.71	Insider Trans	-2.34%	Shs Float	47.94M	Perf Month	-23.32%
Enterprise Value	267.90M	PEG	-	EPS next Q	-0.21	Inst Own	97.27%	Short Float	5.84%	Perf Quarter	-5.44%
Income	-56.78M	P/S	2.20	EPS this Y	155.76%	Inst Trans	-0.70%	Short Ratio	6.33	Perf Half Y	-5.65%
Sales	190.26M	P/B	0.88	EPS next Y	-150.99%	ROA	-6.29%	Short Interest	2.80M	Perf YTD	-13.02%
Book/sh	9.45	P/C	0.99	EPS next 5Y	37.25%	ROE	-9.96%	52W High	11.45 -27.07%	Perf Year	24.53%
Cash/sh	8.41	P/FCF	-	EPS past 3/5Y	26.16% -35.29%	ROIC	-7.68%	52W Low	4.58 82.31%	Perf 3Y	-61.07%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	0.86% 46.42%	Gross Margin	39.46%	Volatility	4.79% 5.30%	Perf 5Y	-88.64%
Dividend TTM	-	EV/Sales	1.41	EPS Y/Y TTM	66.42%	Oper. Margin	-25.55%	ATR (14)	0.48	Perf 10Y	431.85%
Dividend Ex-Date	-	Quick Ratio	15.01	Sales Y/Y TTM	-15.86%	Profit Margin	-29.84%	RSI (14)	30.69	Recom	1.22
Dividend Gr. 3/5Y	- -	Current Ratio	15.77	EPS Q/Q	-612.40%	SMA20	-12.68%	Beta	1.70	Target Price	13.22
Payout	-	Debt/Eq	0.45	Sales Q/Q	-21.94%	SMA50	-14.41%	Rel Volume	0.77	Prev Close	8.24
Employees	1186	LT Debt/Eq	0.44	Earnings	Nov 04 AMC	SMA200	-2.46%	Avg Volume	442.44K	Price	8.35
IPO	Jan 31, 2005	Option/Short	Yes / Yes	EPS/Sales Surpr.	19.14% 7.36%	Trades		Volume	340,213	Change	1.33%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-06-25	Upgrade	Leerink Partners	Market Perform → Outperform	$16
Aug-06-25	Upgrade	KeyBanc Capital Markets	Sector Weight → Overweight
Jul-22-25	Resumed	Stephens	Overweight	$13
Mar-24-25	Upgrade	UBS	Neutral → Buy	$10
Dec-19-24	Initiated	Guggenheim	Buy	$11
Aug-07-24	Downgrade	Jefferies	Buy → Hold	$20 → $8
Jul-31-24	Upgrade	B. Riley Securities	Neutral → Buy	$19 → $15
May-03-24	Downgrade	B. Riley Securities	Buy → Neutral	$22 → $19
Apr-04-24	Resumed	Jefferies	Buy	$17 → $21
Mar-13-24	Reiterated	Needham	Buy	$19 → $18
Aug-17-23	Initiated	Morgan Stanley	Equal-Weight	$16
Aug-10-23	Downgrade	Stephens	Overweight → Equal-Weight	$15
Jul-18-23	Downgrade	UBS	Buy → Neutral	$28 → $17
Jul-17-23	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Jul-13-23	Downgrade	SVB Securities	Outperform → Market Perform	$30 → $10
Jan-19-22	Upgrade	ROTH Capital	Neutral → Buy	$90
Nov-05-21	Downgrade	ROTH Capital	Buy → Neutral	$78 → $90
Oct-19-21	Resumed	B. Riley Securities	Buy	$81
Jul-16-21	Initiated	BTIG Research	Buy	$80
Mar-15-21	Initiated	UBS	Buy	$84

Show Previous Ratings

Feb-11-26 08:30AM	Cryoport's MVE Biological Solutions Introduces New Fusion 800 Series (PR Newswire)
08:16AM	EXCLUSIVE: New Fusion 800 Launch Signals Cryoport's Ambition To Modernize Cryogenic Storage (Benzinga)
Nov-05-25 12:09AM	CryoPort Inc (CYRX) Q3 2025 Earnings Call Highlights: Double-Digit Growth and Strategic ... (GuruFocus.com) -7.48%
Nov-04-25 05:50PM	CryoPort, Inc. (CYRX) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Cryoport Reports Third Quarter 2025 Financial Results (PR Newswire)
08:01AM	Loading…
Nov-03-25 08:01AM	Earnings To Watch: CryoPort Inc (CYRX) Reports Q3 2025 Result (GuruFocus.com)
Oct-30-25 08:30AM	Cryoport Continues to Set New Benchmarks for the Global Regenerative Medicine Supply Chain (PR Newswire)
Oct-21-25 08:00AM	Cryoport to Report Third Quarter 2025 Financial Results on November 4, 2025 (PR Newswire)
Oct-17-25 04:09AM	CryoPort (CYRX) Moves 7.0% Higher: Will This Strength Last? (Zacks) -5.51%
Oct-07-25 08:30AM	MVE Biological Solutions, A Cryoport Company, Introduces Real-Time Integrated Condition Monitoring Systems For Cryogenic Dewars (PR Newswire)
Oct-01-25 08:30AM	Cryoport Systems Expands Global Footprint with New Global Supply Chain Center in Paris, France (PR Newswire)
Aug-06-25 03:32AM	CryoPort Inc (CYRX) Q2 2025 Earnings Call Highlights: Strong Revenue Growth Amid Strategic ... (GuruFocus.com) +29.82%
Aug-05-25 06:35PM	CryoPort, Inc. (CYRX) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -5.87%
04:19PM	Cryoport Reports Second Quarter 2025 Financial Results (PR Newswire)
Aug-04-25 05:55PM	Freightcar America (RAIL) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
10:02AM	Loading…
10:02AM	Earnings To Watch: CryoPort Inc (CYRX) Reports Q2 2025 Result (GuruFocus.com)
Jul-31-25 05:25PM	Hub Group (HUBG) Beats Q2 Earnings Estimates (Zacks)
10:00AM	DHL Group Sponsored ADR (DHLGY) Earnings Expected to Grow: Should You Buy? (Zacks)
Jul-29-25 10:00AM	CryoPort, Inc. (CYRX) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Jul-25-25 09:55AM	CryoPort, Inc. (CYRX) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
Jul-22-25 08:00AM	Cryoport to Report Second Quarter 2025 Financial Results on August 5, 2025 (PR Newswire) +10.73%
Jul-08-25 08:00AM	Cryoport's MVE Biological Solutions Introduces Next Generation Vapor Shippers (PR Newswire)
07:45AM	EXCLUSIVE: Cryoport Boosts Cold Chain Tech With New Shippers Designed For Delays And Rough Handling (Benzinga)
Jul-04-25 12:00PM	What Makes CryoPort, Inc. (CYRX) a Strong Momentum Stock: Buy Now? (Zacks)
Jun-27-25 12:00PM	CryoPort (CYRX) Upgraded to Buy: Here's What You Should Know (Zacks)
Jun-12-25 08:00AM	Cryoport Completes CRYOPDP Divestiture and Commences Strategic Partnership with DHL Group (PR Newswire)
May-28-25 09:55AM	Wall Street Analysts Believe CryoPort (CYRX) Could Rally 81.43%: Here's is How to Trade (Zacks)
May-12-25 09:55AM	Does CryoPort (CYRX) Have the Potential to Rally 54.74% as Wall Street Analysts Expect? (Zacks)
May-08-25 03:34AM	CryoPort Inc (CYRX) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com) +23.32%
May-07-25 07:15PM	Cryoport outlines 2025 revenue guidance and highlights DHL partnership for growth (Seeking Alpha)
07:15PM	Loading…
07:15PM	Cryoport, Inc. (CYRX) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:20PM	CryoPort, Inc. (CYRX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Cryoport Reports First Quarter 2025 Financial Results (PR Newswire)
May-06-25 09:35AM	Expeditors International (EXPD) Q1 Earnings and Revenues Surpass Estimates (Zacks)
Apr-30-25 10:01AM	CryoPort, Inc. (CYRX) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Apr-24-25 08:30AM	Cryoport to Report First Quarter 2025 Financial Results on May 7, 2025 (PR Newswire) +5.37%
Apr-10-25 10:39AM	C.H. Robinson (CHRW) Surges 5.7%: Is This an Indication of Further Gains? (Zacks)
Apr-04-25 06:03AM	UBS Says Its Time to Go Bargain Hunting; Here Are 2 Stocks Poised for a Rebound (TipRanks)
Mar-31-25 03:11PM	Cryoport, Inc. (CYRX) Strategic Agreement and Transaction with DHL Group Call (Transcript) (Seeking Alpha)
09:06AM	DHL Group acquires CRYOPDP from Cryoport to strengthen 'DHL Health Logistics' (PR Newswire)
08:09AM	Cryoport to Host Investor Call to Discuss Recent Strategic Agreement and Transformative Transaction Today, March 31, 2025, at 8:30 a.m. ET (PR Newswire)
Mar-26-25 09:15AM	A Deep Look At Cryoport's Dead Cat Bounce (SeekingAlpha)
Mar-18-25 07:59PM	Is Cryoport, Inc. (CYRX) a Pump and Dump Stock Favored by Hedge Funds? (Insider Monkey) -5.35%
Mar-13-25 07:28AM	CryoPort (CYRX) Surges 5.9%: Is This an Indication of Further Gains? (Zacks) -11.36%
Mar-12-25 08:30AM	Cryoport's MVE Biological Solutions Expands High-Efficiency Cryogenic Freezer Series With Answer to Evolving Needs of Fertility Clinics, Biorepositories and Clinical Laboratories (PR Newswire) +5.86%
Mar-05-25 02:10AM	CryoPort Inc (CYRX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amid Market Challenges (GuruFocus.com) +30.63%
Mar-04-25 05:35PM	CryoPort, Inc. (CYRX) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +5.53%
04:10PM	Cryoport Reports Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
Mar-03-25 07:18AM	CryoPort Inc (CYRX) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com) -13.91%
Feb-18-25 08:30AM	Cryoport to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025 (PR Newswire)
Jan-21-25 08:30AM	Cryoport Unveils State-of-the-Art Cryogenic Shipping System for Transporting Lifesaving Biologics and Temperature-Sensitive Therapies (PR Newswire) +8.80%
Jan-14-25 08:30AM	Moffitt Cancer Center and Cryoport Announce Strategic Collaboration (PR Newswire) -10.73%
Jan-06-25 08:30AM	Cryoport's MVE Biological Solutions Registers All Manufacturing Facilities with the U.S. Food and Drug Administration ('FDA') (PR Newswire)
Nov-12-24 08:30AM	Cryoport Expands IntegriCell Cryopreservation Services Solution with Opening of New Center of Excellence in Europe (PR Newswire)
Nov-08-24 04:03PM	CryoPort Inc (CYRX) Q3 2024 Earnings Call Highlights: Strong Service Growth Amid Market Challenges (GuruFocus.com)
Nov-07-24 05:55PM	CryoPort, Inc. (CYRX) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Cryoport Reports Third Quarter 2024 Financial Results (PR Newswire)
Nov-06-24 07:37AM	CryoPort Inc (CYRX) Q3 2024: Everything You Need to Know Ahead of Earnings (GuruFocus.com)
Oct-31-24 10:01AM	CryoPort, Inc. (CYRX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-29-24 08:30AM	Cryoport to Report Third Quarter 2024 Financial Results on November 7, 2024 (PR Newswire)
Oct-22-24 08:30AM	Cryoport and Gulf Coast Regional Blood Center Launch Strategic Alliance to Enhance Cellular Therapy Services (PR Newswire)
Oct-21-24 08:30AM	TMRW Life Sciences and Cryoport Systems Form Strategic Partnership to Elevate Standards for Frozen Egg, Embryo, and Sperm Offsite Storage and Biologistics (PR Newswire)
Oct-15-24 08:30AM	VGXI Selects Cryoport for Biostorage, Bioservices and Supply Chain Solutions to Advance Next-Generation Therapies (PR Newswire)
Oct-07-24 08:30AM	Cryoport Launches its IntegriCell Cryopreservation Solution with Opening of New Facility at its Houston Campus (PR Newswire)
Sep-25-24 08:30AM	SK pharmteco and Cryoport Partner for Cell and Gene Therapy Logistics and BioServices (PR Newswire)
Sep-09-24 05:28AM	Should You Hold Cryoport (CYRX)? (Insider Monkey) -5.75%
Aug-19-24 03:27AM	Should You be Optimistic on the Growth Prospects of CryoPort (CYRX)? (Insider Monkey)
Aug-06-24 07:00PM	CryoPort, Inc. (CYRX) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:15PM	Cryoport Reports Second Quarter 2024 Financial Results (PR Newswire)
04:05PM	Cryoport Announces $200 Million Repurchase Program and the Repurchase of $160 Million of Convertible Senior Notes (PR Newswire)
Jul-23-24 08:30AM	Cryoport to Report Second Quarter 2024 Financial Results on August 6, 2024 (PR Newswire) -5.54%
Jul-12-24 02:46AM	CryoPort (CYRX) Moves 26.7% Higher: Will This Strength Last? (Zacks)
Jul-09-24 09:35AM	CryoPort (CYRX) Loses -43.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) -5.51%
Jun-20-24 08:30AM	Cryoport and Minaris Regenerative Medicine Form Strategic Partnership to Support Advancement of Cell and Gene Therapies (PR Newswire)
May-17-24 02:33AM	Insider Sale: Director Richard Berman Sells 8,105 Shares of CryoPort Inc (CYRX) (GuruFocus.com) -7.39%
May-08-24 02:54PM	Cryoport, Inc. (NASDAQ:CYRX) Q1 2024 Earnings Call Transcript (Insider Monkey) -19.51%
04:03AM	CryoPort Inc (CYRX) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges with ... (GuruFocus.com)
May-07-24 09:56PM	CYRX Stock Earnings: CryoPort Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
06:18PM	CryoPort Inc (CYRX) Q1 2024 Earnings: Revenue Declines Amid Challenges, Yet Maintains Full-Year ... (GuruFocus.com)
04:08PM	Cryoport Reports First Quarter 2024 Financial Results (PR Newswire)
May-03-24 10:12AM	B. Riley Downgrades Cryoport to Neutral From Buy, Adjusts Price Target to $19 From $22 (MT Newswires) -7.05%
06:41AM	B. Riley Downgrades Cryoport to Neutral From Buy, Cuts Price Target to $19 From $22 (MT Newswires)
Apr-30-24 08:30AM	Cryoport to Report First Quarter 2024 Financial Results on May 7, 2024 (PR Newswire)
Apr-25-24 10:02AM	Earnings Preview: CryoPort, Inc. (CYRX) Q1 Earnings Expected to Decline (Zacks)
Mar-13-24 09:16AM	Cryoport, Inc. (NASDAQ:CYRX) Q4 2023 Earnings Call Transcript (Insider Monkey) -11.90%
Mar-12-24 05:52PM	CryoPort Inc (CYRX) Reports Mixed Financial Results Amidst Global Challenges (GuruFocus.com)
05:30PM	CryoPort, Inc. (CYRX) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Cryoport Reports Fourth Quarter and Full Year 2023 Financial Results (PR Newswire)
Feb-27-24 08:30AM	Cryoport to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 (PR Newswire) +5.95%
Feb-15-24 10:00AM	Analysts Estimate CryoPort, Inc. (CYRX) to Report a Decline in Earnings: What to Look Out for (Zacks)
Feb-13-24 09:55AM	Should You Buy CryoPort, Inc. (CYRX) After Golden Cross? (Zacks) -8.87%
Nov-27-23 08:30AM	Cryoport and NIPPON EXPRESS HOLDINGS Form Global Strategic Partnership for Temperature-Controlled Supply Chain Services (PR Newswire)
Nov-21-23 03:26PM	Consultant's Insight: Cryoport expands its cold-chain supply chain capabilities (Air Cargo World)
Nov-16-23 08:30AM	Cryoport's CRYOPDP Expands U.S. Footprint with Acquisition of Bluebird Express (PR Newswire)
Nov-09-23 05:23PM	Cryoport, Inc. (NASDAQ:CYRX) Q3 2023 Earnings Call Transcript (Insider Monkey) +10.03%
Nov-08-23 06:05PM	CryoPort Inc (CYRX) Faces Economic Headwinds but Sees Growth in Key Segments (GuruFocus.com)
04:05PM	Cryoport Reports Third Quarter 2023 Financial Results (PR Newswire)
Nov-02-23 08:30AM	Cryoport Continues its Expansion in the European Market with Tec4med Lifescience GmbH Acquisition (PR Newswire)
Oct-26-23 10:02AM	Analysts Estimate CryoPort, Inc. (CYRX) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-25-23 08:30AM	Cryoport to Report Third Quarter 2023 Financial Results on November 8, 2023 (PR Newswire) -6.36%

CryoPort, Inc. engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers. It offers personalized medicine, immunotherapies, cellular therapies, CAR T-cell therapies, stem cell therapies, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, bio-pharmaceuticals, infectious substances, and other commodities that require continuous exposure to certain ranges of precision-controlled temperatures. The company was founded on May 25, 1990 and is headquartered in Brentwood, TN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mandalam Ramkumar	Director	Dec 10 '25	Sale	9.99	11,570	115,540	80,758	Dec 12 05:30 PM
RAMKUMAR MANDALAM	Director	Dec 10 '25	Proposed Sale	9.99	11,570	115,540		Dec 10 04:10 PM
Hariri Robert J	Director	Sep 11 '25	Option Exercise	2.66	50,000	133,000	76,275	Sep 12 05:30 PM
Hariri Robert J	Director	Sep 11 '25	Sale	9.71	25,000	242,738	51,275	Sep 12 05:30 PM
ROBERT HARIRI	Director	Sep 11 '25	Proposed Sale	9.71	25,000	242,738		Sep 11 04:29 PM
Hariri Robert J	Director	Aug 22 '25	Sale	8.60	5,000	43,000	26,275	Aug 29 06:46 PM
STEFANOVICH ROBERT	Chief Financial Officer	Aug 19 '25	Option Exercise	3.07	26,164	80,323	216,513	Aug 21 05:00 PM
STEFANOVICH ROBERT	Chief Financial Officer	Aug 19 '25	Sale	8.67	9,300	80,618	207,213	Aug 21 05:00 PM
ROBERT S. STEFANOVICH	Officer	Aug 19 '25	Proposed Sale	8.67	9,300	80,618		Aug 19 04:40 PM
SHELTON JERRELL	President, CEO	Aug 13 '25	Option Exercise	5.00	25,000	125,000	1,062,419	Aug 15 05:00 PM
SHELTON JERRELL	President, CEO	Jul 31 '25	Option Exercise	5.00	25,000	125,000	1,037,419	Aug 04 06:00 PM
SHELTON JERRELL	President, CEO	Jul 24 '25	Option Exercise	5.00	25,000	125,000	1,012,419	Jul 28 05:04 PM
Mandalam Ramkumar	Director	Jul 22 '25	Option Exercise	3.07	60,000	184,200	133,056	Jul 24 05:00 PM
Mandalam Ramkumar	Director	Jul 22 '25	Sale	7.24	40,728	294,899	92,328	Jul 24 05:00 PM
SHELTON JERRELL	President, CEO	Jul 18 '25	Option Exercise	5.00	25,000	125,000	987,419	Jul 22 04:52 PM
RAMKUMAR MANDALAM	Director	Jul 22 '25	Proposed Sale	6.71	40,728	273,285		Jul 22 04:10 PM
SHELTON JERRELL	President, CEO	Jul 08 '25	Option Exercise	5.00	25,000	125,000	962,419	Jul 10 05:00 PM
SHELTON JERRELL	President, CEO	Jun 25 '25	Option Exercise	5.00	25,000	125,000	937,419	Jun 26 08:00 PM
SHELTON JERRELL	President, CEO	Jun 24 '25	Option Exercise	5.00	16,344	81,720	928,763	Jun 26 08:00 PM
SHELTON JERRELL	President, CEO	Jun 24 '25	Sale	7.06	16,344	115,366	912,419	Jun 26 08:00 PM
Mandalam Ramkumar	Director	Jun 24 '25	Option Exercise	3.07	20,000	61,400	86,377	Jun 26 08:00 PM
Mandalam Ramkumar	Director	Jun 24 '25	Sale	7.01	13,321	93,447	73,056	Jun 26 08:00 PM
RAMKUMAR MANDALAM	Director	Jun 24 '25	Proposed Sale	6.56	13,321	87,386		Jun 24 04:09 PM
SHELTON JERRELL	President, CEO	Jun 17 '25	Option Exercise	5.00	201,304	1,006,520	1,063,723	Jun 20 08:15 PM
SHELTON JERRELL	President, CEO	Jun 18 '25	Option Exercise	5.00	119,281	596,405	1,031,700	Jun 20 08:15 PM
SHELTON JERRELL	President, CEO	Jun 20 '25	Option Exercise	5.00	69,135	345,675	981,554	Jun 20 08:15 PM
SHELTON JERRELL	President, CEO	Jun 17 '25	Sale	6.81	151,304	1,029,715	912,419	Jun 20 08:15 PM
SHELTON JERRELL	President, CEO	Jun 18 '25	Sale	6.81	119,281	812,542	912,419	Jun 20 08:15 PM
SHELTON JERRELL	President, CEO	Jun 20 '25	Sale	6.47	69,135	447,525	912,419	Jun 20 08:15 PM
JERRELL W SHELTON	Director	Jun 17 '25	Proposed Sale	6.93	356,064	2,467,524		Jun 17 04:14 PM
Mandalam Ramkumar	Director	Jun 11 '25	Sale	7.06	8,193	57,816	68,896	Jun 13 07:00 PM
Mandalam Ramkumar	Director	Jun 12 '25	Sale	7.01	1,895	13,286	67,001	Jun 13 07:00 PM
Mandalam Ramkumar	Director	Jun 13 '25	Sale	6.80	624	4,246	66,377	Jun 13 07:00 PM
RAMKUMAR MANDALAM	Director	Jun 13 '25	Proposed Sale	6.80	624	4,246		Jun 13 04:12 PM
RAMKUMAR MANDALAM	Director	Jun 12 '25	Proposed Sale	7.01	1,895	13,286		Jun 12 04:18 PM
RAMKUMAR MANDALAM	Director	Jun 11 '25	Proposed Sale	7.01	8,193	57,463		Jun 11 04:21 PM
ZECCHINI EDWARD J	Chief Digital and Tech Officer	Jun 10 '25	Option Exercise	3.07	75,000	230,250	141,911	Jun 10 07:28 PM
ZECCHINI EDWARD J	Chief Digital and Tech Officer	Jun 10 '25	Sale	6.84	51,500	352,518	90,411	Jun 10 07:28 PM
Mandalam Ramkumar	Director	Jun 09 '25	Sale	7.06	5,622	39,673	77,089	Jun 10 07:25 PM
EDWARD ZECCHINI	Officer	Jun 10 '25	Proposed Sale	6.84	51,500	352,512		Jun 10 04:29 PM
RAMKUMAR MANDALAM	Director	Jun 09 '25	Proposed Sale	7.06	5,622	39,673		Jun 09 05:33 PM
SHELTON JERRELL	President, CEO	Jun 04 '25	Option Exercise	5.00	50,000	250,000	862,419	Jun 06 02:21 PM
Hariri Robert J	Director	May 28 '25	Sale	6.10	12,500	76,250	8,061	May 30 07:00 PM
Sawicki Mark W	Chief Scientific Officer	Mar 24 '25	Sale	6.94	1,349	9,364	84,087	Mar 26 07:01 PM
STEFANOVICH ROBERT	Chief Financial Officer	Mar 24 '25	Sale	6.94	1,070	7,428	190,349	Mar 26 07:00 PM
SHELTON JERRELL	President, CEO	Mar 24 '25	Sale	6.94	2,980	20,686	762,419	Mar 26 07:00 PM
ZECCHINI EDWARD J	Chief Digital and Tech Officer	Mar 17 '25	Sale	6.29	1,140	7,173	66,911	Mar 18 07:08 PM
STEFANOVICH ROBERT	Chief Financial Officer	Mar 17 '25	Sale	6.29	1,659	10,438	191,419	Mar 18 07:07 PM
Sawicki Mark W	Chief Scientific Officer	Mar 17 '25	Sale	6.29	2,092	13,162	85,436	Mar 18 07:06 PM
SHELTON JERRELL	President, CEO	Mar 17 '25	Sale	6.29	4,620	29,068	765,399	Mar 18 07:05 PM
Sawicki Mark W	Chief Scientific Officer	Mar 09 '25	Option Exercise	0.00	2,667	0	80,111	Mar 11 07:01 PM
Sawicki Mark W	Chief Scientific Officer	Mar 10 '25	Sale	4.88	1,583	7,724	78,528	Mar 11 07:01 PM
SHELTON JERRELL	President, CEO	Mar 09 '25	Option Exercise	0.00	8,250	0	744,192	Mar 11 07:01 PM
SHELTON JERRELL	President, CEO	Mar 10 '25	Sale	4.88	4,173	20,360	740,019	Mar 11 07:01 PM
STEFANOVICH ROBERT	Chief Financial Officer	Mar 09 '25	Option Exercise	0.00	2,667	0	184,334	Mar 11 07:00 PM
STEFANOVICH ROBERT	Chief Financial Officer	Mar 10 '25	Sale	4.88	1,256	6,128	183,078	Mar 11 07:00 PM

BIVI

BioVie Inc

CYRX

CryoPort Inc

Upgrade your FINVIZ experience